IP Library Granted Patent US 9,949,923
Granted Patent B2
US 9,949,923 · App. 14/005,363 · Granted Apr 24, 2018

Nasal delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,923
App. No.
14/005,363
Granted
Apr 24, 2018
Kind
B2
Abstract

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

Claims (18)

1. A method of treating 22q11.2 deletion syndrome, comprising

delivering from about 1 IU to about 100 IU of a substance selected from the group consisting of oxytocin, carbetocin, and demoxytocin to the upper posterior, olfactory region of the nasal airway.

2. The method of claim 1 , wherein the substance is delivered as a powder.

3. The method of claim 1 , wherein the substance is delivered as a liquid.

4. The method of claim 1 , wherein the substance is delivered as a powder, followed by application of a liquid.

5. The method of claim 1 , wherein the substance includes a thickening agent, which thickens following delivery on exposure to moisture, thereby increasing residency of the substance at the upper posterior, olfactory region of the nasal airway, wherein the thickening agent comprises pectin, agar-agar, lignin, algin, gums, and/or cellulose.

6. The method of claim 1 , wherein the substance is delivered in a once-daily administration or twice-daily administration.

7. The method of claim 1 , wherein the delivery of the substance is targeted to provide for one or both of nose-to-brain (N 2 B) and systemic delivery.

8. The method of claim 1 , wherein the substance is mixed with lactose.

9. A method of treating 22q11.2 deletion syndrome, comprising delivering oxytocin to the upper posterior, olfactory region of the nasal airway.

10. The method of claim 9 , wherein about 1 IU to about 100 IU of oxytocin is delivered.

11. The method of claim 9 , wherein the oxytocin is delivered as a powder.

12. The method of claim 9 , wherein the oxytocin is delivered as a liquid.

13. The method of claim 9 , wherein the oxytocin is delivered as a powder, followed by application of a liquid.

14. The method of claim 9 , further including delivering a thickening agent, which thickens following delivery on exposure to moisture to thereby increase residency of oxytocin at the upper posterior, olfactory region of the nasal airway.

15. The method of claim 14 , wherein the thickening agent comprises pectin, agar-agar, lignin, algin, gums, and/or cellulose.

16. The method of claim 9 , wherein delivery of the oxytocin is targeted to provide for one or both of nose-to-brain (N2B) and systemic delivery.

17. The method of claim 9 , further including delivering lactose with the oxytocin.

Assignments (10)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71337/0132 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: OPTINOSE, INC.
Reel/Frame 075101/0804 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: OPTINOSE, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0018 →
SECURITY INTEREST Recorded May 22, 2025
From: OPTINOSE, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071337/0132 →
RELEASE OF SECURITY INTEREST Recorded May 21, 2025
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: OPTINOSE INC.
Reel/Frame 071547/0979 →
CHANGE OF ADDRESS Recorded Jan 8, 2025
From: OPTINOSE, INC.
To: OPTINOSE, INC.
Reel/Frame 069848/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: OPTINOSE AS
To: OPTINOSE INC
Reel/Frame 061546/0424 →
SECURITY INTEREST Recorded Sep 13, 2019
From: OPTINOSE AS
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 050371/0913 →
RELEASE OF SECURITY AGREEMENT RECORDED AT REEL 044976 FRAME 0505 Recorded Sep 13, 2019
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: OPTINOSE AS
Reel/Frame 050371/0894 →
SECURITY INTEREST Recorded Dec 29, 2017
From: OPTINOSE AS
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 044976/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2013
From: DJUPESLAND, PER GISLE
To: OPTINOSE AS
Reel/Frame 031672/0629 →